{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:48:35Z","timestamp":1791474515765,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jneuroim.2022.577958","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:34:57Z","timestamp":1663241697000},"page":"577958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Management of neurosarcoidosis"],"prefix":"10.1016","volume":"372","author":[{"given":"Desmond P.","family":"Kidd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2022.577958_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.10.003","article-title":"Neuroimaging findings in intracranial sarcoid phlebitis: a case report","volume":"28","author":"Bathla","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001063","article-title":"Vascular involvement in neurosarcoidosis: early experience from intracranial vessel wall imaging","volume":"8","author":"Bathla","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12016-015-8492-9","article-title":"Treatment of sarcoidosis","volume":"49","author":"Baughman","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0020","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1212\/WNL.0b013e3181ec7ff9","article-title":"A case of neurosarcoidosis successfully treated with rituximab","volume":"75","author":"Bomprezzi","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0035","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen-Aubart","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000452","article-title":"Symptomatic muscular sarcoidosis: lesson from a nationwide multicentre study","author":"Cohen-Aubart","year":"2018","journal-title":"Neurol. Neuroinflamm. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0050","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of multiorgan sarcoidosis with tofacitinib","volume":"3","author":"Damsky","year":"2020","journal-title":"ARC Open Rheumatol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0060","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarc. Vasc. Diffuse Lung. Dis."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0065","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1097\/RHU.0000000000000900","article-title":"Novel use of rituximab in treatment refractory neurosarcoidosis in an 11 year old girl","volume":"25","author":"Earle","year":"2019","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0075","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0080","first-page":"45","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Natl. Rev."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mus.10541","article-title":"Sarcoid polyneuropathy responsive to intravenous immunoglobulin","volume":"29","author":"Heaney","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0022-510X(69)90086-0","article-title":"Sarcoidosis of the central nervous system","volume":"9","author":"Herring","year":"1969","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0095","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00415-021-10793-2","article-title":"Adalimumab for CNS sarcoidosis: single center experience and review","volume":"269","author":"Hutto","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence","author":"James","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicentre study of 132 patients","volume":"47","author":"Jamilloux","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0110","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0115","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarc. Vasc. Diffuse Lung. Dis."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0120","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00415-018-8928-2","article-title":"Sarcoidosis of the central nervous system: clinical features, imaging and CSF results","volume":"265","author":"Kidd","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2019-002349","article-title":"Neurosarcoidosis: a review of the clinical manifestations, investigation results and treatment","volume":"20","author":"Kidd","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0130","doi-asserted-by":"crossref","first-page":"105811","DOI":"10.1016\/j.clineuro.2020.105811","article-title":"Sarcoidosis of the central nervous system: safety and efficacy of treatment, and experience of biological therapies","volume":"194","author":"Kidd","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clineuro.2018.03.019","article-title":"Carotid arteritis causing amaurosis fugax and ischaemic cerebrovascular events in neurosarcoidosis","volume":"169","author":"Kidd","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0140","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1212\/WNL.0000000000009526","article-title":"Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar","volume":"94","author":"Kidd","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3340\/jkns.2009.45.1.50","article-title":"Moyamoya-like vasculopathy in Neurosarcoidosis","volume":"45","author":"Ko","year":"2009","journal-title":"J. Korean Neurosurg. Soc."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mus.20683","article-title":"Granulomatous myositis: a clinical study of thirteen cases","volume":"35","author":"Le Roux","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-009-0077-1","article-title":"Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab","volume":"256","author":"Marnane","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0160","first-page":"741","article-title":"A systemic review of physical activity and physical fitness in sarcoidosis","volume":"4","author":"Morton-Holtham","year":"2021","journal-title":"TSM"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-1331.2012.03783.x","article-title":"Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature","volume":"20","author":"O\u2019Dwyer","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1440-1843.2009.01518.x","article-title":"Clinical outcomes in sarcoidosis after cessation of infliximab treatment","volume":"14","author":"Panselinas","year":"2009","journal-title":"Respirology"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00415-019-09234-y","article-title":"Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment","volume":"266","author":"Riller","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12254-019-0506-5","article-title":"Risk of cancer after long-term therapy of auto-immune disorders with glucocorticoids and DMARDs \u2013 a controversial issue","volume":"12","author":"Rudski","year":"2019","journal-title":"Memo"},{"key":"10.1016\/j.jneuroim.2022.577958_bb0185","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/B978-0-444-52902-2.00027-8","article-title":"Sarcoidosis of the peripheral nervous system","volume":"115","author":"Said","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0190","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/1744666X.2016.1175301","article-title":"Biologic therapies in the treatment of sarcoidosis","volume":"12","author":"Saketkoo","year":"2016","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0195","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"Sharp","year":"2019","journal-title":"Respir. Med. J."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fibre neuropathy in a large cohort: clinical aspects and response to IVIg and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2017.05.030","article-title":"Neurosarcoidosis and multiple intracerebral hematomas: an unusual clinical presentation","volume":"379","author":"Vukojevic","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2022.577958_bb0215","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418805732","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","volume":"11","author":"Zella","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:55Z","timestamp":1759048915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":43,"alternative-id":["S0165572822001539"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577958","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of neurosarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577958"}}